Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06160076
Other study ID # CHUBX 2023/33
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 16, 2023
Est. completion date December 16, 2024

Study information

Verified date November 2023
Source University Hospital, Bordeaux
Contact Pierre JAÏS, MD, PhD
Phone +33 5 57 65 64 71
Email pierre.jais@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. Catheter ablation using pulmonary vein isolation (PVI) in an established treatment strategy for AF. Pulsed Field Ablation (PFA) is a non-thermal ablation modality which has recently been introduced in clinical practice with the aim of improving PVI efficacy and safety. The aim of this study is to analyse whether PFA generates a lower inflammatory reaction as compared to conventional radiofrequency ablation (RFA).


Description:

Pulmonary vein isolation represents the cornerstone of AF ablation. PFA is a novel non-thermal cardiac ablation modality which is currently studied in clinical trials for the treatment of AF with promising efficacy and safety results. PFA is reported to generate less collateral damage by inducing selective apoptosis of cardiomyocytes, while other structures such as nerves, vessels and oesophageal tissue remain spared. PFA lesions show more organized and homogeneous fibrosis on histopathological study as compared to thermal lesions. In a recent study conducted at Hôpital Haut-Lévêque, PFA was associated with 20% less acute oedema on magnetic resonance imaging. Therefore, PFA may generate a reduced inflammatory reaction which could translate into lower early recurrence rates, less post-procedural chest pain and improved clinical outcomes. Data on the systemic inflammation generated by PFA and RFA is still lacking. The aim of this study is to analyse the inflammatory reaction after PFA and RFA in patients referred for first-time catheter ablation of paroxysmal AF. For this purpose, established biomarkers of systemic inflammation (leucocytosis, platelet-monocyte-complexes, inflammatory cytokines) will be determined in blood samples collected from patients treated with either PFA or RFA. The collection of blood samples will be exclusively performed during routine blood drawing at three time points: at the beginning of the procedure (to define baseline values), at the end of the procedure (to measure acute inflammation) and the day following the procedure (to define inflammation occurring within 24 hours). Clinical signs of inflammation (fever, chest pain, pericardial fluid) and early arrhythmia recurrences will also be assessed the day after the ablation. On a routine 6-month follow-up visit, late arrhythmia recurrences will be registered. In a secondary analysis, the thrombogenic and pro-arrhythmogenic potential of both ablation modalities and the predictive value of inflammatory biomarkers for early and late recurrences will be assessed.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date December 16, 2024
Est. primary completion date April 16, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 100 Years
Eligibility Inclusion Criteria: - Age = 18 years - Patients with paroxysmal AF referred for first-time catheter ablation using PFA or RFA - Non-opposition to participate Exclusion Criteria: - Age < 18 years - Persons under judicial protection (guardianship, guardianship) or deprived of freedom - Prior left atrial ablation - Prior cardiac surgery comprising incision of the left atrium - Prior myocardial infarction or stroke in the previous 30 days - Acute or chronic inflammatory state: active smoking, auto-immune disease, active tumor disease, myocarditis - Antiplatelet therapy (e.g. aspirine, clopidogrel) within the 7 last days - Anti-inflammatory treatment (e.g. glucocorticoids, colchicine, cyclophosphamide, azathioprine, mycophenolic acid, antibodies) within the 7 last days

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiofrequency
Patient with atrial fibrillation ablated per catheter using radiofrequency energy
Pulsed electric field
Patient with atrial fibrillation ablated per catheter using pulsed electric field

Locations

Country Name City State
France Hôpital Haut-Lévèque Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acute thromboinflammatory response Circulating platelet-monocyte complexes (PMC) 24 hours
Primary Systemic inflammatory response (IL-6) Changes in leukocyte count and circulating levels of IL-6 24 hours
Primary Systemic inflammatory response (TNF-a) Changes in leukocyte count and circulating levels of TNF-a 24 hours
Primary Systemic inflammatory response (CRP) Changes in leukocyte count and circulating levels of CRP 24 hours
Primary Pericarditis Chest pain suggestive of pericarditis assessed using a numeric pain rating scale (0 to 10) 24 hours
Secondary Incidence of early arrhythmias Incidence of early arrhythmias occurring during the post-operative period on telemetry in PFA vs. RFA 24 hours
Secondary Analysis of biomarkers (CD40L) Platelet activation: Changes in plasma levels of soluble CD40L 24 hours
Secondary Analysis of biomarkers (Willebrand) Endothelial cell damage: Changes in plasma levels of von Willebrand factor 24 hours
Secondary Incidence of late atrial arrhythmia recurrence Atrial fibrillation and/or atrial tachycardia recurrences documented by Holter-ECGs or other wearable devices 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A